Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
chemotherapy/hemorrhage
Lyen an sove nan clipboard la
Paj 1 soti nan 16 rezilta yo
Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to compositions comprising membrane-derived microparticles that promote platelet adhesion, aggregation, blood clot formation and to a method for treating bleeding disorders, particularly blood coagulation disorders, platelet
Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
Hematological disorders are blood associated disorders. Blood is a highly specialized tissue which carries oxygen and nutrients to all parts of the body and waste products back to the lungs, kidneys and liver for disposal. Thus, blood maintains communication between
Process for inhibiting platelet aggregation
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula I to the plasma surrounding the platelets.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the Formula I are old compounds
Process for inhibiting platelet aggregation
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula I to the plasma surrounding the platelets.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the Formula I are old compounds
Process of treatment
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula I to the plasma surrounding the platelets.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the Formula I are old compounds
Thrombocytopoiesis stimulating factor
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TECHNICAL FIELD
The present invention relates to a novel physiologically active substance (thrombocytopoiesis stimulating factor) having activity in acting on cells in the megakaryocyte system, in promoting their differentiation and maturation, and in promoting the formation of platelets, as well as
Acetylcholinesterase-derived peptides and uses thereof
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The invention is directed to the field of stem cell survival and expansion. Specifically, the invention is directed at the stem cell survival and expansion effects of peptides derived from acetylcholinesterase. In addition, the invention relates to a system for screening of
Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment, the
Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula 1 to the plasma surrounding the platelets.
DETAILED DESCRIPTION
The compounds of the Formula 1 are old compounds known in the art.
Process for inhibiting platelet aggregation
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula 1 to the plasma surrounding the platelets.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the Formula 1 are old compounds
Process for treating elevated platelet adhesiveness
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula 1 to the plasma surrounding the platelets.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the Formula 1 are old compounds
Human G-protein coupled receptor
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Antibodies immunospecific for a novel human G-protein coupled receptor family
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
